HIMS

Hims & Hers Health announced the acquisition of Eucalyptus, a telehealth company, to expand its operations into Australia, Canada, and Japan. The deal marks Hims & Hers' first major international expansion beyond the United States. Terms of the acquisition were not disclosed in the article.

Hims & Hers Health has completed its acquisition of Eucalyptus, the Australian parent company of health brands Juniper, Pilot, Kin, and Software. The deal marks Hims & Hers' official entry into the Australian market and extends its reach to over half a million existing Eucalyptus customers. The company positions the combined entity as the world's largest consumer health platform.

Hims & Hers Health has expanded its platform to allow clinicians to prescribe Eli Lilly GLP-1 treatments (Zepbound vials, KwikPen, and Foundayo) fulfilled via LillyDirect, while also broadening access to Novo Nordisk therapies. The company additionally acquired a facility to strengthen peptide capabilities ahead of an FDA review on compounding. These moves deepen HIMS's role in prescription weight management and could materially shift its product mix.

Eli Lilly's new oral GLP-1 weight-loss drug is reportedly seeing prescription volumes trail Novo Nordisk's oral Wegovy. JPMorgan has initiated coverage on Hims & Hers Health. Regeneron is offering a new hearing-loss therapy at no cost.

CNBC highlights stocks with the largest midday price moves, including Intel, AMD, Charter, Hims & Hers, and Eli Lilly, among others. The article serves as a market roundup without providing specific details on the direction or magnitude of each move. No individual company news or catalysts are elaborated upon in the available text.

Hims & Hers Health is pivoting away from GLP-1 compounding, announcing it will allow providers to prescribe scripts filled through LillyDirect, Eli Lilly's direct-to-consumer platform. The move marks a strategic retreat from compounded GLP-1 drugs, which had been a key growth driver for the company. The stock is falling on the news, as the so-called "Netflix" argument — that Hims could build a subscription-based weight-loss platform — loses credibility.

Hims & Hers Health announced it will allow providers on its platform to prescribe medications fulfilled through LillyDirect, Eli Lilly's direct-to-consumer pharmacy service. The deal signals a shift in Hims & Hers' business model toward partnering with branded drug manufacturers rather than competing solely on compounded or generic alternatives. Hims stock dropped on the news, likely reflecting concerns about margin pressure or competitive dynamics.